PDF(Pubmed)
Abstract：
Influenza vaccines play a vital role in protecting individuals from influenza virus infection and severe illness. However, current influenza vaccines have suboptimal efficacy, which is further reduced in cases where the vaccine strains do not match the circulating strains. One strategy to enhance the efficacy of influenza vaccines is by extended antigen delivery, thereby mimicking the antigen kinetics of a natural infection. Prolonging antigen availability was shown to quantitatively enhance influenza virus-specific immune responses but how it affects the quality of the induced immune response is unknown. Therefore, the current study aimed to investigate whether prolongation of the delivery of influenza vaccine improves the quality of the induced immune responses over that induced by prime-boost immunization.
Mice were given daily doses of whole inactivated influenza virus vaccine for periods of 14, 21, or 28 days; the control group received prime-boost immunization with a 28 days interval.
Our data show that the highest levels of cellular and humoral immune responses were induced by 28 days of extended antigen delivery, followed by 21, and 14 days of delivery, and prime-boost immunization. Moreover, prolonging vaccine delivery also improved the quality of the induced antibody response, as indicated by higher level of high avidity antibodies, a balanced IgG subclass profile, and a higher level of cross-reactive antibodies.
Our findings contribute to a better understanding of the immune response to influenza vaccination and have important implications for the design and development of future slow-release influenza vaccines.
Mice were given daily doses of whole inactivated influenza virus vaccine for periods of 14, 21, or 28 days; the control group received prime-boost immunization with a 28 days interval.
Our data show that the highest levels of cellular and humoral immune responses were induced by 28 days of extended antigen delivery, followed by 21, and 14 days of delivery, and prime-boost immunization. Moreover, prolonging vaccine delivery also improved the quality of the induced antibody response, as indicated by higher level of high avidity antibodies, a balanced IgG subclass profile, and a higher level of cross-reactive antibodies.
Our findings contribute to a better understanding of the immune response to influenza vaccination and have important implications for the design and development of future slow-release influenza vaccines.
摘要：
流感疫苗在保护个体免受流感病毒感染和严重疾病的影响方面发挥着至关重要的作用。然而,目前的流感疫苗效果欠佳，在疫苗毒株与循环毒株不匹配的情况下进一步降低。增强流感疫苗功效的一种策略是通过延长抗原递送，从而模拟自然感染的抗原动力学。延长的抗原可用性显示定量增强流感病毒特异性免疫应答,但其如何影响诱导的免疫应答的质量是未知的。因此,本研究旨在调查延长流感疫苗的递送时间是否比初次加强免疫所诱导的免疫应答质量更好.
给小鼠每日剂量的全灭活流感病毒疫苗,为期14、21或28天;对照组接受间隔28天的初免-加强免疫。
■我们的数据表明，延长28天的抗原递送可诱导最高水平的细胞和体液免疫反应，其次是21天和14天的交货时间，和强化免疫。此外，延长疫苗递送也提高了诱导的抗体反应的质量，高亲合力抗体水平较高，平衡的IgG亚类概况，和更高水平的交叉反应抗体。
■我们的发现有助于更好地了解流感疫苗接种的免疫反应，并对未来缓释流感疫苗的设计和开发具有重要意义。
给小鼠每日剂量的全灭活流感病毒疫苗,为期14、21或28天;对照组接受间隔28天的初免-加强免疫。
■我们的数据表明，延长28天的抗原递送可诱导最高水平的细胞和体液免疫反应，其次是21天和14天的交货时间，和强化免疫。此外，延长疫苗递送也提高了诱导的抗体反应的质量，高亲合力抗体水平较高，平衡的IgG亚类概况，和更高水平的交叉反应抗体。
■我们的发现有助于更好地了解流感疫苗接种的免疫反应，并对未来缓释流感疫苗的设计和开发具有重要意义。
